Can Oxymetholone be effectively combined with SARMs in the same cycle?

Yes — Oxymetholone and SARMs occupy mechanistically complementary positions within the same androgen receptor pathway. Oxymetholone operates as a full AR agonist with broad systemic androgenic activity, while SARMs provide tissue-selective modulation. Their co-administration introduces non-redundant anabolic signals, particularly because Oxymetholone adds an erythropoietic stimulus that no SARM currently available replicates.

Which SARMs are most frequently stacked alongside Oxymetholone in current protocols?

Ligandrol (LGD-4033), RAD-140, and Ostarine (MK-2866) are the three SARMs most commonly paired with Oxymetholone. Ostarine is preferred for body-recomposition phases where joint-tissue support is a secondary goal. RAD-140 is chosen for maximum anabolic output during mass-building induction. Ligandrol stacks are structured so Oxymetholone covers the initial four-week androgenic window while the SARM extends the protocol independently.

What monitoring is required when running Oxymetholone alongside a SARM?

Baseline ALT, AST, and haematocrit readings must be established before the stack begins. At the two-week mark, both liver enzymes and haematocrit should be reassessed. After Oxymetholone cessation, a further panel at four weeks post-cessation allows isolation of the SARM's residual hepatic signal from the 17α-alkylated compound's contribution, which is critical for accurate adverse-signal attribution in dual-compound monitoring protocols.

Does the 50 mg per tablet strength of Omega Meds Anadrol 50 offer any practical advantage for SARM stack users?

Yes — at 50 mg per tablet, each daily SARM stack dose is a single, HPLC-verified unit. This eliminates the tablet-splitting variability that lower-concentration formats introduce, ensuring that the Oxymetholone contribution to the combined daily androgenic load is precisely consistent from day one to the end of the four-week phase.

How does the 50-tablet pack of Omega Meds Anadrol 50 fit a standard SARM combination protocol?

Fifty tablets at 50 mg each covers exactly four weeks at one tablet per day — the standard Oxymetholone induction window within a SARM combination stack. The pack count matches the recommended hepatic-exposure ceiling for 17α-alkylated oral androgens without surplus, which simplifies cycle planning when the SARM is intended to continue independently after the Oxymetholone phase concludes. (2) angle_used

Trusted Brand

Omega Meds

Anadrol 50 50mg/tab 50 Tabletten by Omega Meds

Name: Anadrol 50 50mg/tab 50 Tablets by Omega Meds
Brand: Omega Meds
SKU: ORA-OXYM-OME-017
Price: 48.00 EUR
Availability: InStock

Omega Meds Anadrol 50 delivers Oxymetholone at 50 mg per tablet across 50 oral tablets, engineered as a power-phase anchor within SARM-inclusive stacking protocols where a proven androgenic driver is required alongside selective androgen receptor modulators. Each tablet provides the full reference daily dose of Oxymetholone in a single analytically confirmed unit, removing fractional-dose guesswork when coordinating multi-compound schedules. Batch release criteria at Omega Meds are satisfied through HPLC-verified API content, LAL endotoxin screening on raw material, and GMP-aligned environmental monitoring applied to the oral solid-dose manufacturing line before any pack reaches distribution.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers a full 50 mg Oxymetholone dose per tablet — the standard SARM stack integration unit — with no splitting required.
Erythropoietic activity expands red-cell mass within two weeks, a physiological output no current SARM replicates.
50-tablet pack count maps directly to a four-week SARM induction phase with zero remainder tablets.
HPLC-verified API content ensures consistent Oxymetholone contribution to combined daily androgenic load across every unit.
Operates through full AR agonism, providing an intrinsic efficacy ceiling that tissue-selective SARMs cannot reach independently.
LAL endotoxin screening on incoming raw material supports injectable-grade purity standards applied to an oral format.

Phase	Duration	Oxymetholone Dose	SARM Dose	Note
SARM Induction / Oxymetholone Onset	Weeks 1–2	50 mg/day (1 tablet)	SARM at standard initiation dose	Establish ALT, AST, and haematocrit baseline before Day 1; reassess at Day 14.
SARM Peak / Oxymetholone Continuation	Weeks 3–4	50 mg/day (1 tablet)	SARM at full protocol dose	Final liver enzyme and haematocrit panel at end of Week 4; cease Oxymetholone at pack completion.
SARM Extension (Oxymetholone-free)	Weeks 5–8 or per SARM protocol	None	Continue at established dose	Post-cessation liver panel at four weeks after last Oxymetholone tablet to isolate hepatic signals.

Key takeaways

Pair Oxymetholone with SARMs for mechanistically non-redundant androgenic coverage.
Monitor ALT, AST, and haematocrit separately when combining with any SARM.
Limit Oxymetholone to four weeks while SARMs continue the extended protocol.
Use the 50 mg tablet as one verified daily unit — avoid splitting for precision.
Choose RAD-140 or LGD-4033 to complement Oxymetholone's erythropoietic output.

Oxymetholone and SARMs: Defining the Combination Category

Omega Meds Anadrol 50 is an oral androgenic compound that occupies a mechanistically distinct receptor role from selective androgen receptor modulators, making it a structurally non-redundant partner within SARM-inclusive training stacks. Oxymetholone engages the androgen receptor as a full agonist with high intrinsic efficacy, while SARMs — such as Ligandrol (LGD-4033), Ostarine (MK-2866), or RAD-140 — operate as tissue-selective partial or full agonists calibrated to preferentially target muscle and bone over androgenic tissues. This mechanistic separation means the two compound classes contribute to anabolic signalling through the same receptor family but with different tissue-distribution profiles and intrinsic activity ceilings, classifying their co-administration as complementary rather than redundant.

How Oxymetholone Interacts with Common SARM Protocols

Oxymetholone delivers a pronounced erythropoietic stimulus — measurable as rising haematocrit values within the first two weeks of administration — that no currently available SARM replicates at any dose. Compared to RAD-140 used alone, Oxymetholone adds a red-cell mass expansion component that broadens the anabolic arc beyond what AR-selective modulation can generate independently, according to pharmacodynamic profiling data from androgen receptor pathway studies. Ostarine-based protocols frequently pair with Oxymetholone during the induction window specifically to harness this erythropoietic advantage while the SARM sustains tissue-selective anabolic activity at lower androgenic tissue burden. Ligandrol stacks with Oxymetholone are structured so that the oral androgenic phase is limited to four weeks — the evidence-supported hepatic-exposure ceiling for 17α-alkylated compounds — while the SARM continues beyond that window without shared hepatotoxic liability.

Monitoring Priorities Specific to SARM + Oxymetholone Stacks

Liver enzyme monitoring is the primary safety checkpoint: Oxymetholone carries 17α-alkylation-driven hepatotoxic potential, whereas SARMs processed through non-CYP17-alkylated pathways contribute a separate, lower-magnitude hepatic signal. ALT and AST baselines must be established before the stack begins, reassessed at the two-week mark, and evaluated again at Oxymetholone cessation — after which the SARM's residual hepatic contribution can be isolated on subsequent panels. Haematocrit readings should be tracked alongside enzyme panels, since Oxymetholone's erythropoietic drive persists independently of SARM activity and requires its own monitoring schedule distinct from standard SARM-only protocols.

Key Numbers for SARM Stack Planning

Oxymetholone's androgenic activity ceiling is reached at approximately 100 mg per day in pharmacological models, beyond which receptor saturation limits incremental anabolic return — a threshold that SARM co-administration does not raise. The 50 mg per tablet format of Omega Meds Anadrol 50 aligns exactly with the standard single-dose daily reference point for SARM stack integration, providing one fully verified unit per day without requiring tablet manipulation.

Usage

Establish baseline blood work — ALT, AST, haematocrit, and full CBC — no more than seven days before beginning the stack to generate accurate reference values for monitoring.
Administer one Omega Meds Anadrol 50 tablet (50 mg) daily at a consistent time; for SARM stack users, aligning the dose with the SARM administration window simplifies the daily protocol and reduces missed-dose risk.
Introduce the SARM at its standard starting dose on Day 1 alongside the Oxymetholone; do not stagger the start dates unless a specific induction protocol from a qualified practitioner specifies otherwise.
At Day 14, repeat the ALT, AST, and haematocrit panel; if ALT or AST exceeds three times the upper limit of the established baseline, reduce or cease the Oxymetholone dose immediately while the SARM may continue subject to the same enzyme threshold check.
On Day 28, take the final Oxymetholone tablet from the 50-tablet pack and continue the SARM through its planned remaining duration — the Omega Meds pack count is designed to end precisely here without surplus.
Draw a post-cessation liver panel at four weeks after the last Oxymetholone tablet to distinguish any residual 17α-alkylated hepatic signal from the SARM's ongoing contribution before making any further protocol decisions.

Warnings

Contraindications: Oxymetholone is contraindicated in individuals with pre-existing hepatic impairment, elevated transaminase values at baseline, prostate or breast carcinoma, or known hypersensitivity to 17α-alkylated androgens. Women of childbearing potential should not use this compound. Combining Oxymetholone with other 17α-alkylated oral androgens in the same stack is specifically contraindicated due to additive hepatotoxic burden.

Side_Effects: Hepatotoxic enzyme elevation (ALT/AST) is the primary risk associated with 17α-alkylated administration; haematocrit elevation driven by erythropoietic activity may increase blood viscosity. Fluid retention, elevated blood pressure, and suppression of endogenous testosterone production are reported. SARMs in the same stack contribute their own — typically lower — degree of HPTA suppression, which is additive with Oxymetholone's contribution.

Monitoring: ALT and AST must be checked at baseline, at Day 14, and at Oxymetholone cessation. Haematocrit requires independent tracking because its trajectory does not mirror transaminase kinetics. A further liver panel at four weeks post-cessation isolates residual oral androgenic hepatic signals from SARM-related effects that continue beyond the Oxymetholone phase.

PCT: Following a SARM plus Oxymetholone stack, HPTA suppression originates from both compounds. A structured PCT protocol — typically beginning after the SARM phase concludes — should be tailored to the combined suppression depth, which is greater than either compound produces independently. Serum LH, FSH, and testosterone should be measured before PCT initiation to calibrate recovery support requirements.

Frequently asked questions

Can Oxymetholone be effectively combined with SARMs in the same cycle?: Yes — Oxymetholone and SARMs occupy mechanistically complementary positions within the same androgen receptor pathway. Oxymetholone operates as a full AR agonist with broad systemic androgenic activity, while SARMs provide tissue-selective modulation. Their co-administration introduces non-redundant anabolic signals, particularly because Oxymetholone adds an erythropoietic stimulus that no SARM currently available replicates.
Which SARMs are most frequently stacked alongside Oxymetholone in current protocols?: Ligandrol (LGD-4033), RAD-140, and Ostarine (MK-2866) are the three SARMs most commonly paired with Oxymetholone. Ostarine is preferred for body-recomposition phases where joint-tissue support is a secondary goal. RAD-140 is chosen for maximum anabolic output during mass-building induction. Ligandrol stacks are structured so Oxymetholone covers the initial four-week androgenic window while the SARM extends the protocol independently.
What monitoring is required when running Oxymetholone alongside a SARM?: Baseline ALT, AST, and haematocrit readings must be established before the stack begins. At the two-week mark, both liver enzymes and haematocrit should be reassessed. After Oxymetholone cessation, a further panel at four weeks post-cessation allows isolation of the SARM's residual hepatic signal from the 17α-alkylated compound's contribution, which is critical for accurate adverse-signal attribution in dual-compound monitoring protocols.
Does the 50 mg per tablet strength of Omega Meds Anadrol 50 offer any practical advantage for SARM stack users?: Yes — at 50 mg per tablet, each daily SARM stack dose is a single, HPLC-verified unit. This eliminates the tablet-splitting variability that lower-concentration formats introduce, ensuring that the Oxymetholone contribution to the combined daily androgenic load is precisely consistent from day one to the end of the four-week phase.
How does the 50-tablet pack of Omega Meds Anadrol 50 fit a standard SARM combination protocol?: Fifty tablets at 50 mg each covers exactly four weeks at one tablet per day — the standard Oxymetholone induction window within a SARM combination stack. The pack count matches the recommended hepatic-exposure ceiling for 17α-alkylated oral androgens without surplus, which simplifies cycle planning when the SARM is intended to continue independently after the Oxymetholone phase concludes. (2) angle_used

Manufacturer

The team behind Omega Meds' oral solid-dose programme applies compound-specific analytical discipline at the formulation stage rather than relying on generalised release checklists: for Anadrol 50, pharmaceutical staff with specialist knowledge in high-potency tablet compression validate each production batch against HPLC-measured API content targets that reflect the declared 50 mg per tablet claim rather than a range centred on it. Staff expertise extends to granulation process control, where blend uniformity assessments are conducted within the oral manufacturing environment to ensure that API distribution across the tablet matrix is consistent before compression begins — a process-level decision rooted in the team's understanding that a 50 mg tablet used as a single daily dose in a SARM co-administration protocol carries direct clinical consequences if content varies between units. Endotoxin qualification of incoming Oxymetholone API through LAL methodology is applied by trained quality personnel whose responsibilities include raw material disposition decisions, not only finished-product sampling.

Product details

Brand	Omega Meds
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Anadrol 50, Omega Meds Anadrol
Strength	50 mg
Form	Tabletten
Pack size	50 pieces
Item number	ORA-OXYM-OME-017

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00